Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Fate Therapeutics, Inc. (FATE)

BridgeBio Oncology Therapeutics, Inc and Fate Therapeutics, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Fate Therapeutics, Inc. are of similar size ($236.5M and $230.7M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −1,941.1%) and the lower return on invested capital (−127.7% vs 0.00%). Across the 12 metrics below, Fate Therapeutics, Inc. leads on 7 and BridgeBio Oncology Therapeutics, Inc on 5.

Valuation

Metric BBOT FATE Biotechnology median
P/E n/m n/m 8.50
P/S n/m 33.20 9.71
P/B 0.70 1.40 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 13.12 9.21
Earnings yield (97.87%) (58.66%) (33.15%)
Free cash flow yield (67.14%) (48.92%) (25.50%)

Profitability

Metric BBOT FATE Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (2,058.08%) 0.00%
Net margin 0.00% (1,941.09%) 0.00%
Free cash flow margin 0.00% (1,624.06%) 0.00%
Return on equity (252.10%) (60.75%) (56.36%)
Return on assets (96.69%) (39.89%) (48.04%)
Return on invested capital (127.66%) 0.00% 0.00%

Growth

Metric BBOT FATE Biotechnology median
Revenue growth (TTM) — (23.36%) 6.02%
EPS growth (last fiscal year) 99.93% 29.88% 30.26%
Revenue growth, 5-year CAGR — (26.71%) 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT FATE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 4.85 4.72
Net debt to EBITDA 2.93 1.47 0.96

Dividend

Metric BBOT FATE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBOT FATE Biotechnology median
Market cap 236.52m 230.65m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack